A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.

sarah Jonas

6 months ago

For this presentation at ASCO 2024, please email the media contact for more information.